Winter T C, Freeny P C, Nghiem H V, Mack L A, Patten R M, Thomas C R, Elliott S
Department of Radiology, University of Washington Medical Center, Seattle 98195.
AJR Am J Roentgenol. 1993 Dec;161(6):1191-8. doi: 10.2214/ajr.161.6.8249724.
The purpose of this study was to evaluate the efficacy of superparmagnetic iron oxide (SPIO) in the detection of focal hepatic lesions on MR images.
The study included 21 patients with 115 focal hepatic lesions and eight patients without focal hepatic lesions. T1- and T2-weighted MR images were obtained at 1.5 T before and 60 min after the end of injection of an SPIO agent. Contrast-enhanced CT scans were obtained in all patients within 10 days after MR imaging. The effect of SPIO on the signal intensity of the liver and spleen was assessed by using quantitative analysis of the region of interest. Efficacy was evaluated by using multiple criteria and unenhanced and SPIO-enhanced images. Evaluations included subjective assessment of image quality, counting the number of lesions detected, and statistical analysis of quantitative changes in the signal intensity of lesions and of normal liver.
By all criteria, SPIO-enhanced T2-weighted MR images were superior to unenhanced T2-weighted images and to contrast-enhanced CT scans. Conversely, by all criteria, SPIO-enhanced T1-weighted MR images were worse than unenhanced T1-weighted images and contrast-enhanced CT scans. The mean lesion-to-liver contrast on T2-weighted images was 317% on unenhanced images and 1745% on SPIO-enhanced images. For T1-weighted, the mean contrast was 26% on unenhanced images and 18% on SPIO-enhanced images.
SPIO is an efficacious contrast agent for the detection of focal hepatic lesions when T2-weighted MR images are used.
本研究旨在评估超顺磁性氧化铁(SPIO)在磁共振成像(MR)中检测肝脏局灶性病变的效能。
本研究纳入了21例患有115个肝脏局灶性病变的患者以及8例无肝脏局灶性病变的患者。在注射SPIO制剂前及注射结束后60分钟,于1.5T磁场下获取T1加权和T2加权MR图像。所有患者在MR成像后10天内均进行了对比增强CT扫描。通过对感兴趣区域进行定量分析,评估SPIO对肝脏和脾脏信号强度的影响。采用多种标准并结合未增强及SPIO增强图像评估效能。评估内容包括图像质量的主观评估、检测到的病变数量计数以及病变和正常肝脏信号强度定量变化的统计分析。
依据所有标准,SPIO增强的T2加权MR图像优于未增强的T2加权图像及对比增强CT扫描。相反,依据所有标准,SPIO增强的T1加权MR图像比未增强的T1加权图像及对比增强CT扫描差。在T2加权图像上,未增强图像的病变与肝脏平均对比度为317%,SPIO增强图像为1745%。对于T1加权图像,未增强图像的平均对比度为26%,SPIO增强图像为18%。
当使用T2加权MR图像时,SPIO是检测肝脏局灶性病变的有效对比剂。